

FILE 'MEDLINE' ENTERED AT 11:54:59 ON 07 AUG 2002

FILE 'CANCERLIT' ENTERED AT 11:54:59 ON 07 AUG 2002

FILE 'CAPPUS' ENTERED AT 11:54:59 ON 07 AUG 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USACERTS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 11:54:59 ON 07 AUG 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 11:54:59 ON 07 AUG 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 11:54:59 ON 07 AUG 2002

COPYRIGHT (C) 2002 El Sevier Science B.V. All rights reserved.

=> s tnf (a) fusion?

L1 84 TNF (A) FUSION?

=> s 11 and immunogl?

L2 32 L1 AND IMMUNOGLOB?

=> s tumor necrosis factor or tnf (a) fusion?

L3 273044 TUMOR NECROSIS FACTOR OR TNF (A) FUSION?

=> s 13 and immunogl?

L4 16661 L3 AND IMMUNOGLOB?

=> s 14 and lt(alpha) or lymphotoxin(alpha)beta

L5 1555 L4 AND LT(A) BETA OR LYMPHOTOXIN(A) BETA

=> s 15 and immunogl?

L6 392 L5 AND IMMUNOGLOB?

=> dup rem 16

PROCESSING COMPLETED FOR L6

L7 307 DUP RM L6 (85 DUPLICATES REMOVED)

=> s 17 not PY=>1998

5 FILES SEARCHED...

'1998; NOT A VALID FIELD CODE

L8 49 L7 NOT PY=>1998

=> d his

(FILE 'HOME' ENTERED AT 11:53:49 ON 07 AUG 2002)

FILE 'MEDLINE, CANCERLIT, CAPPUS, USPATFULL, BIOSIS, CONFSCI, EMBASE'

ENTERED AT 11:54:59 ON 07 AUG 2002

L1 84 TNF (A) FUSION?

L2 32 S L1 AND IMMUNOGLOB?

L3 273044 S TUMOR NECROSIS FACTOR OR TNF (A) FUSION?

L4 16661 S L3 AND IMMUNOGLOB?

L8 ANSWER 1 OF 49 MEDLINE

AN 1998014593 MEDLINE

DN 90014593 PubMed ID: 9354470

TI Developing lymph nodes collect CD4+CD3- lTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells.

AU Mebius R E; Renner P C; Weissman I L

CS Department of Cell Biology and Immunology, Faculty of Medicine, Vrije Universiteit, Amsterdam, The Netherlands. r.mebius.cell@med.vu.nl

NC CA42551 (NCI)

SO IMMUNITY. (1997 Oct) 7 (4) 493-504.

Journal code: 9332918. ISSN: 1074-7613.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 19971105 Entered STN: 19971124

ED Last Updated on STN: 2000003103

Entered Medline: 19971121

L8 ANSWER 2 OF 49 MEDLINE

AN 97461446 MEDLINE

DN 97461446 PubMed ID: 9317127

TI Characterization of lymphotxin-alpha beta complexes on the surface of mouse lymphocytes.

AU Browning J L; Sizing I D; Lawton P; Bourdon P R; Rennert P D; Majeau G R; Ambrose C M; Hession C; Matkowsky K; Griffiths D A; Ngam-ek A; Meier W; Benjamin C D; Hochman P S

CS Department of Immunology, Biogen, Cambridge, MA 02142, USA.. Jeff.Browning@biogen.com

SO JOURNAL OF IMMUNOLOGY. (1997 Oct 1) 159 (7) 3288-98.

Journal code: 2985117R. ISSN: 0022-1767.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 199710 Entered STN: 19971105

ED Last Updated on STN: 19971105

Entered Medline: 19971021

L8 ANSWER 3 OF 49 MEDLINE

AN 97439485 MEDLINE

DN 97439486 Published ID: 9295042

TI Lymphotxin but not tumor necrosis factor maintains splenic architecture and humoral responsiveness in adult mice.

AU Mackay F; Majeau G R; Lawton P; Hochman P S; Browning J L; Biogen, Cambridge, MA 02142, USA.. fabienne-mackay@biogen.com

CS Department of Immunology, Inflammation and Cell Biology, Biogen, Cambridge, MA 02142, USA.. fabienne-mackay@biogen.com

SO EUROPEAN JOURNAL OF IMMUNOLOGY. (1997 Aug) 27 (8) 2033-42.

Journal code: 1273201. ISSN: 0014-2990.

CY GERMANY; Germany; Federal Republic of

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199709

L8 ANSWER 1 OF 49 MEDLINE

AN 1998014593 MEDLINE

DN 90014593 PubMed ID: 9354470

TI Developing lymph nodes collect CD4+CD3- lTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells.

AU Mebius R E; Renner P C; Weissman I L

CS Department of Cell Biology and Immunology, Faculty of Medicine, Vrije Universiteit, Amsterdam, The Netherlands. r.mebius.cell@med.vu.nl

NC CA42551 (NCI)

SO IMMUNITY. (1997 Oct) 7 (4) 493-504.

Journal code: 9332918. ISSN: 1074-7613.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 19971105 Entered STN: 19971124

ED Last Updated on STN: 2000003103

Entered Medline: 19971121

L8 ANSWER 2 OF 49 MEDLINE

AN 97461446 MEDLINE

DN 97461446 PubMed ID: 9317127

TI Characterization of lymphotxin-alpha beta complexes on the surface of mouse lymphocytes.

AU Browning J L; Sizing I D; Lawton P; Bourdon P R; Rennert P D; Majeau G R; Ambrose C M; Hession C; Matkowsky K; Griffiths D A; Ngam-ek A; Meier W; Benjamin C D; Hochman P S

CS Department of Immunology, Biogen, Cambridge, MA 02142, USA.. Jeff.Browning@biogen.com

SO JOURNAL OF IMMUNOLOGY. (1997 Oct 1) 159 (7) 3288-98.

Journal code: 2985117R. ISSN: 0022-1767.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 199710 Entered STN: 19971105

ED Last Updated on STN: 19971105

Entered Medline: 19971021

L8 ANSWER 3 OF 49 MEDLINE

AN 97439485 MEDLINE

DN 97439486 Published ID: 9295042

TI Lymphotxin but not tumor necrosis factor maintains splenic architecture and humoral responsiveness in adult mice.

AU Mackay F; Majeau G R; Lawton P; Hochman P S; Browning J L; Biogen, Cambridge, MA 02142, USA.. fabienne-mackay@biogen.com

CS Department of Immunology, Inflammation and Cell Biology, Biogen, Cambridge, MA 02142, USA.. fabienne-mackay@biogen.com

SO EUROPEAN JOURNAL OF IMMUNOLOGY. (1997 Aug) 27 (8) 2033-42.

Journal code: 1273201. ISSN: 0014-2990.

CY GERMANY; Germany; Federal Republic of

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199709

ED	Entered STN: 197013	AN	97075125	MEDLINE
	Last Updated on STN: 1997013	DN	97075125	Published ID: 891751
	Entered Medline: 19970930	TI		Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble lymphotxin-beta receptor-IG3I fusion protein.
L8	ANSWER 4 OF 49 MEDLINE	AU	Ettlinger R; Browning J L; Michie S A; van Swijk W; McDevitt H O	
AN	97278851	CS	Department of Microbiology and Immunology, Stanford University School of Medicine, CA 94305, USA.	
DN	97278851 Pubmed ID: 9133428	NC	AI-3535 (NCI)	
TI	Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotxin beta-deficient mice.	SO	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1996 Nov 12) 93 (23) 13102-7.	
AU	Koni P A; Saccà R; Lawton P; Browning J L; Ruddle N H; Flavell R A	Journal code: 7505876. ISSN: 0027-8424.		
DN	Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut 06520, USA.	LA	English	
NC	R01 AI34404 (NCI)	LA	Priority Journals	
SO	IMMUNITY, (1997 Apr) 6 (4) 491-500.	DT	Journal; Article; (JOURNAL ARTICLE)	
CY	Journal code: 9432918. ISSN: 1074-7613.	FS		
DT	United States	EM		
LA	English	ED		
FS	Priority Journals	ED		
EM	199705	ED		
ED	Entered STN: 19970523	ED		
	Last Updated on STN: 19970523	ED		
	Entered Medline: 19970513	ED		
L8	ANSWER 5 OF 49 MEDLINE	ED		
AN	97180895	ED		
DN	97180895 Pubmed ID: 9029113	ED		
TI	Activation of the $\gamma_2$ lymphotxin beta receptor by cross-linking induces production and growth arrest in A375 melanoma cells.	ED		
AU	DeGi-Resposti M A; Davis-Smith T; Din W S; Smolak P J; Goodwin R G; Smith C A	ED		
CS	Department of Biochemistry, Immunex Corporation, Seattle, WA 98101, USA.	ED		
SO	JOURNAL OF IMMUNOLOGY, (1997 Feb 15) 158 (4) 1756-62.	ED		
CY	Journal code: 2915117R. ISSN: 0022-1767.	ED		
DT	United States	ED		
LA	English	ED		
FS	Priority Journals	ED		
EM	199703	ED		
ED	Entered STN: 19970313	ED		
	Last Updated on STN: 19970313	ED		
	Entered Medline: 19970305	ED		
L8	ANSWER 6 OF 49 MEDLINE	ED		
AN	97079154	ED		
DN	97079154 Pubmed ID: 8920886	ED		
TI	Surface lympho toxin alpha/beta complex is required for the development of peripheral lymphoid organs.	ED		
AU	Rennert P D; Browning J L; Mebius R; Mackay F; Hochman P S	ED		
CS	Biogen Inc., Cambridge, Massachusetts 02142, USA.	ED		
SO	JOURNAL OF EXPERIMENTAL MEDICINE, (1996 Nov 1) 184 (5) 1999-2006.	ED		
CY	Journal code: 2915103R. ISSN: 0022-1707.	ED		
DT	United States	ED		
LA	English	ED		
FS	Priority Journals	ED		
EM	199612	ED		
ED	Entered STN: 19961208	ED		
	Last Updated on STN: 19961208	ED		
	Entered Medline: 19961230	ED		
L8	ANSWER 7 OF 49 MEDLINE	ED		
	Entered Medline: 19940822	ED		

LA	ANSWER 10 OF 49	MEDLINE	TI	Development and characterization of ouabain-resistant human fusion
AN	9300236	MEDLINE	AU	partners.
DN	93008266	PUBLISHED ID: 135634	AU	Kamakamida R; Barczy I; Rector E S; Sehon A H
TI	Stimulation of JFN-gamma, TNF-alpha, and TNF-beta secretion in	CS	Department of Immunology, Faculty of Medicine, University of Manitoba,	
	IL-2-activated T cells: costimulatory roles for LFA-1, LFA-2, CD44, and	SO	Winnipeg, Canada.	
	CD45 molecules.	TI	JOURNAL OF IMMUNOLOGICAL METHODS. (1991 Aug 28) 142 (1) 21-9.	
AU	Chong A S; Boushey I A; Graf L H; Scuderi P	SO	Journal code: 1305440. ISSN: 0022-1759.	
CS	Department of General Surgery, Rush-Presbyterian-St. Luke's Medical	CY	Netherlands	
center, Chicago, Illinois 60612.	Journal code: 1146405. ISSN: 0008-8749.	CY	Journal: Article; (JOURNAL ARTICLE)	
NC	1 R29 CA53805-01A1 (NCI)	DT	Journal: Article; (JOURNAL ARTICLE)	
SO	CELLULAR IMMUNOLOGY. (1992 Oct 1) 144 (1) 69-79.	LA	English	
CY	United States	FS	Priority Journals	
DT	Entered Medline: 19921028	EM	199111	
LA	Journal: Article; (JOURNAL ARTICLE)	ED	Entered STN: 19920124	
FS	Priority Journals	ED	Last Updated on STN: 19970203	
EM	Entered STN: 19920122	ED	Entered Medline: 19921028	
EM	Last Updated on STN: 19970203	ED	Last Updated on STN: 19970203	
LA	Priority Journals	ED	Last Updated on STN: 19970203	
EM	Entered Medline: 19920122	ED	Entered Medline: 19921028	
EM	Entered STN: 19920925	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920925	ED	Entered Medline: 19921028	
EM	Last Updated on STN: 19920925	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered Medline: 19920917	ED	Entered Medline: 19921028	
LA	ANSWER 12 OF 49	MEDLINE	ED	Entered Medline: 19921028
AN	92323605	MEDLINE	ED	Entered Medline: 19921028
DN	92323605	PUBLISHED ID: 1352484	ED	Entered Medline: 19921028
TI	Properties of monoclonal antibodies to human tumor necrosis factor alpha	ED	Entered Medline: 19921028	
AU	(TNF alpha).	ED	Entered Medline: 19921028	
CS	McLaughlin P J; Elwood N J; Russell S M; Andrew S M; McKenzie I F	ED	Entered Medline: 19921028	
SO	Department of Immunology, University of Liverpool, U.K.	ED	Entered Medline: 19921028	
CY	ANTICANCER RESEARCH (1992 JUL-AUG) 12 (4) 1243-6.	ED	Entered Medline: 19921028	
Journal code: 8102398. ISSN: 0250-7005.	ED	Entered Medline: 19921028		
CY	Greece	ED	Entered Medline: 19921028	
DT	Journal; Article; (JOURNAL ARTICLE)	ED	Entered Medline: 19921028	
LA	English	ED	Entered Medline: 19921028	
FS	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920925	ED	Entered Medline: 19921028	
EM	Last Updated on STN: 19920925	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered Medline: 19920917	ED	Entered Medline: 19921028	
LA	ANSWER 12 OF 49	MEDLINE	ED	Entered Medline: 19921028
AN	92323605	MEDLINE	ED	Entered Medline: 19921028
DN	92323605	PUBLISHED ID: 1352484	ED	Entered Medline: 19921028
TI	IL-3 dependence of a Thy-110, B220+, IL-3 receptor-positive	ED	Entered Medline: 19921028	
AU	antigen-specific BTH-initiating clone.	ED	Entered Medline: 19921028	
AU	Millet I; Ferreri N R; Ramabhadran R; Akenase P W	ED	Entered Medline: 19921028	
CS	Department of Internal Medicine, Yale University School of Medicine, New	ED	Entered Medline: 19921028	
CS	Haven, Connecticut 06510.	ED	Entered Medline: 19921028	
NC	AI-122211 (NIHAD)	ED	Entered Medline: 19921028	
SO	AI-26689 (NIHAD)	ED	Entered Medline: 19921028	
SO	CELLULAR IMMUNOLOGY. (1992 Aug) 143 (1) 154-69.	ED	Entered Medline: 19921028	
Journal code: 1216405. ISSN: 0008-8749.	ED	Entered Medline: 19921028		
CY	United States	ED	Entered Medline: 19921028	
DT	Journal; Article; (JOURNAL ARTICLE)	ED	Entered Medline: 19921028	
LA	English	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821	ED	Entered Medline: 19921028	
ED	Last Updated on STN: 19950206	ED	Entered Medline: 19921028	
LA	Entered Medline: 19920811	ED	Entered Medline: 19921028	
LA	Priority Journals	ED	Entered Medline: 19921028	
EM	Entered STN: 19920821</td			

L8	ANSWER 17 OF 49 CAPLUS COPYRIGHT 2002 ACS	PI	The University of California, Oakland, CA, United States (U.S. corporation)
AN	19971253389 CARLUS	AI	US 5670149 19970923
DN	126-276255	RLI	US 1995-476489 19950606 (8)
TI	Role of T cells in the mediation of Heymann nephritis. II. Identification of TIL and cytotoxic cells in glomeruli of the kidney. Mark J.; Boyd, Rochelle A.; Hall, Bruce M. Dep. Medicine, Univ. New South Wales, Liverpool Hospital, New South Wales, Australia	Continuation of Ser. No. US 1994-22614, filed on 1 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1990-544862, filed on 27 Jun 1990, now abandoned	
AU		DT	Utility Granted
CS		FS	
SO	Kidney International (1997), 51(4), 1059-1068	IN CNT	25/94
CO/DE:	KDYIAS; ISSN: 0085-2538	INCL	INCLIM: 424/130.100
PB	Blackwell	INCLS:	424/133.100; 424/139.100; 424/141.100; 424/142.100; 424/145.100;
DT	Journal	INCLM:	424/158.100; 435/069.500; 530/388.220; 530/388.240
LA	English	INCLCS:	424/133.1.1; 424/141.1; 424/142.1; 424/145.1; 424/158.1
L8	ANSWER 18 OF 49 USPATFULL	IC	[61] 424/158.100; 435/069.500; 530/388.220; 530/388.240
TI	Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies	EXP	435/69.5; 435/172.1; 435/320.1; 530/388.22; 530/388.24; 424/130.1; 424/133.1; 424/141.1; 424/142.1; 424/145.1; 424/158.1
IN	Le, Junning, Jackson Heights, NY, United States	CAS	INDEXING IS AVAILABLE FOR THIS PATENT.
PA	Vilcek, Jan, New York, NY, United States	L8	ANSWER 20 OF 49 USPATFULL
	Daddona, Peter, Menlo Park, CA, United States	AN	97-75989 USPATFULL
	Ghazayeb, John, Thordale, PA, United States	PA	Lymphotoxin- <i>beta</i> , Lymphotoxin- <i>beta</i> , complexes, pharmaceutical preparations and therapeutic uses thereof
	Knight, David, Berwyn, PA, United States	PI	Browning, Jeffrey, Brookline, MA, United States
	New York University Medical Center, New York, NY, United States (U.S. corporation)	AI	Ware, Carl F., Riverside, CA, United States
PI	Centocor, Inc., Malvern, PA, United States (U.S. corporation)	RLI	Bigen, Inc., Cambridge, MA, United States (U.S. corporation)
AI	US 5698195 19971216	IN	University of California, Oakland, CA, United States (U.S. corporation)
RLI	US 5694-324739 19941018 (8)	PA	US 5661004 19970826
	Continuation-in-part of Ser. No. US 1994-192102, filed on 4 Feb 1994, now abandoned and Ser. No. Ser. No. US 1994-192061, filed on 4 Feb 1994, now abandoned each Ser. No. US - which is a continuation-in-part of Ser. No. US 1993-10406, filed on 29 Jan 1993, now abandoned and Ser. No. US 1993-13413, filed on 2 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-943552, filed on 11 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-855606, filed on 18 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-670827, filed on 18 Mar 1991, now abandoned	PI	US 5661004 1994-1922614, filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No. US 1992-990304, filed on 4 Dec 1992, now abandoned which is a continuation of Ser. No. US 1990-544862, filed on 27 Jun 1990, now abandoned
DT	Utility	AI	Continuation of Ser. No. US 1994-22614, filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No. US 1992-990304, filed on 4 Dec 1992, now abandoned which is a continuation of Ser. No. US 1990-544862, filed on 27 Jun 1990, now abandoned
FS	Granted	RLI	
IN	IN CNT	IN	
LN CNT	5887	INCL	INCLIM: 435/069.100
INCL	INCIM: 424/133.100	INCL	INCLCS: 435/1240.200; 536/023.500
INCL	INCLS: 424/141.100; 424/145.100; 424/192.100; 514/825.000; 530/387.300;	INCLM:	435/065.100
NCL	530/388.230; 530/351.000	INCLCS:	435/325.000; 435/358.000; 435/366.000; 435/372.300; 536/023.500
NCL	530/388.230	IC	[61]
NCLM:	530/388.100	ICM:	C12N015.00
NCLC:	530/388.230	ICCS:	C12N015.11; C12N015.85
EXF	530/387.300; 530/388.100; 530/388.230	EXF	435/69.5; 435/69.1; 435/240.2; 536/23.5
		CAS	INDEXING IS AVAILABLE FOR THIS PATENT.
L8	ANSWER 21 OF 49 USPATFULL	IN	
AN	97-70718 USPATFULL	IN	ANSWER 21 OF 49 USPATFULL
TI	Methods of treating TNF- <i>alpha</i> -mediated Crohn's disease using chimeric anti-TNF antibodies	PA	Le, Junning, Jackson Heights, NY, United States
	Vilcek, Jan, New York, NY, United States	PA	Daddona, Peter, Palo Alto, CA, United States
	Ghazayeb, John, Thordale, PA, United States	PA	Ghazayeb, John, Thordale, PA, United States
	Knight, David, Berwyn, PA, United States	PA	Knight, David, Berwyn, PA, United States
	New York University Medical Center, New York, NY, United States (U.S. corporation)	PA	Centocor, Inc., Malvern, PA, United States (U.S. corporation)
PI	US 5656272	PI	

AI	US 1994-19210;	19940204 (8)	DT	Utility
RLI	Continuation-in-part of Ser. No. US 1993-10406, filed on 26 Jan 1993, now abandoned. And Ser. No. US 1993-11413, filed on 2 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-943852, filed on 11 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-853606, filed on 18 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-670827, filed on 18 Mar 1991, now abandoned		NCL	530/328.000; 530/329.000; 530/330.000
LN CNT	5231.	INCL	NCLM:	514/013.000
INCL	INCIM: 424/132.100		NCIS:	514/012.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000;
INCL	INCLS: 424/135.100; 424/139.100; 435/069.100; 435/069.600; 435/069.700;			514/018.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000;
NCL	530/387.300; 530/388.230			530/338.000; 530/329.000; 530/330.000
IC	[61] ICM: A61K039-395	IC	[61]	ICM: A61K038-000
ICM:	C12P021-05; C12P021-04; C12P021-08	ICCS:	C07K007-00	
EXF	424/138.1; 424/810; 435/169.6; 435/172.2; 435/70.21; 435/240.27; 935/15;	EXF	514/118; 530/327; 530/328; 530/329; 530/330; 530/326	
CAS	530/388.23; 530/389.2; 530/804	CAS	INDEXING IS AVAILABLE FOR THIS PATENT.	
L8	ANSWER 22 OF 49 USPATFULL			
AN	97-56799 USPATFULL	L8	ANSWER 24 OF 49 USPATFULL	
TI	Tumour necrosis factor binding ligands	AN	97-8000 USPATFULL	
Rathjen, Deborah Ann, New South Wales, Australia		TI	Tumour necrosis factor mutanteins	
Aston, Roger, Gloucester, Great Britain		IN	Banner, David, Basle, Switzerland	
PA	Peptide Technology Ltd., Australia (non-U.S. corporation)		Leisslauer, Werner, Riehen, Switzerland	
PI	US 5644034		Loescher, Hansruedi, Moabit, Germany	
AI	US 1994-344133		Stuber, Dietrich, Grenzach-Wyhlen, Germany	
RLI	Continuation-in-part of Ser. No. US 1992-828956, filed on 18 Feb 1992, now abandoned		Federal Republic of	
PRAI	AU 1993-5662		Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)	
	1993007		US 5597899	
	AU 1993-1576		US 1994-217529	
DT	WO 1990-AU337		EP 093-810224 (8)	
FS	19900807		PRAI	
LN CNT	14.93		EP 093-810224	19930329
INCL	INCIM: 530/388.230		DT	Utility
INCL	INCIS: 530/388.240; 530/389.100; 530/389.200		FS	Utility
NCL	530/388.230		INCL	Granted
NCL	530/388.240; 530/389.100; 530/389.200		INCL	1506
IC	[61]		INCL	INCLM: 530/351.000
ICM:	C07K014-525		INCL	INCIM: 435/069.500; 435/069.100; 530/402.000
EXF	530/351; 435/69.1; 435/69.5		INCL	INCIS: 435/069.100; 435/069.500; 530/402.000
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.		INCL	NCIS: 435/069.100; 435/069.500; 530/402.000
L8	ANSWER 25 OF 49 USPATFULL		INCL	NCIS: 435/069.100; 435/069.500; 530/402.000
AN	96-43511 USPATFULL		INCL	NCIS: 435/069.100; 435/069.500; 530/402.000
TI	Tumour necrosis factor inhibitors		IN	
Heeunver, George A., Malvern, PA, United States				
Kruszynski, Marian, West Chester, PA, United States				
Mervic, Miljenko, King of Prussia, PA, United States				
Weber, Robert W., Downingtown, PA, United States				
PA	Centecor, Inc., Malvern, PA, United States (U.S. corporation)			
PT	US 5519000			
AI	US 1994-221580			
DT	19940401 (8)			
UTL				
FS				
INCL	Granted			
LN CNT	1410			
INCL	INCIM: 514/012.000			
INCL	INCIS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000;			
INCL	514/018.000; 530/324.000; 530/326.000; 530/328.000; 530/329.000;			
NCL	530/330.000			
NCL	INCIM: 514/012.000			
NCIS:	514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000;			
NCIS:	514/018.000; 530/324.000; 530/326.000; 530/328.000; 530/329.000;			
NCIS:	530/330.000			
IC	[61]			
ICM: A61K03-00				
ICM: C07K007-04; C07K014-00				
EXF	530/324; 530/326; 530/328; 530/329; 530/330; 514/12; 514/13; 514/14;			
CAS	514/15; 514/16; 514/17; 514/18			
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.			
L8	ANSWER 26 OF 49 USPATFULL			

AN	96:29567 USPATFULL	ICM: A61K038-19
TI	Tumor necrosis factor inhibitors	ICG: C07K014-52
IN	Heavner, George A., Malvern, PA, United States (U.S. corporation)	530/350; 530/350; 424/85.1; 424/545; 424/198.1; 514/2; 514/8; 514/12;
PA	Centecor, Inc., Malvern, PA, United States (U.S. corporation)	435/240.2
PI	US 5,063,310	19960409
AI	US 1,94-221581	19940401 (8)
DT	Utility	Granted
FS		
LN/CNT	1053	
INCL	INCIM: 530/324.000	
INCLS:	530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000;	
INCL	530/330.000	
INCLM:	530/324.000	
INCLS:	530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000;	
INCL	530/330.000	
IC	[6]	
ICM:	C07K005-0)	
ICG:	C07K007-0); C07K017-00	
EXF	514/2-16; 530/324-330	
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.	
L8	ANSWER 27 OF 49 USPATFULL	
AN	96:7/81 USPATFULL	
TI	Tumor necrosis factor inhibitors	
IN	Heavner, George A., Malvern, PA, United States (U.S. corporation)	
PA	Centecor, Inc., Malvern, PA, United States (U.S. corporation)	
PI	US 5,065,595	19960123
AI	US 1,934-221583	19940401 (8)
DT	Utility	
FS	Granted	
LN/CNT	2105	
INCL	INCIM: 530/324.000	
INCL	INCIM: 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000;	
INCL	530/330.000	
INCLM:	530/324.000	
INCLS:	530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000;	
INCL	530/330.000	
IC	[6]	
ICM:	C07K005-00	
ICG:	C07K007-00; C07K017-00	
EXF	530/324-330; 511/12-18	
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.	
L8	ANSWER 28 OF 49 USPATFULL	
AN	95:5/890 USPATFULL	
TI	Method of activating T cells with lymphokine SAF	
IN	DeFreitas, Elaine, Villanova, PA, United States	
PA	Adams, J. Todd, Narberth, PA, United States	
PI	University of Miami, Miami, FL, United States (U.S. corporation)	
AI	US 5,277,81	19950527
DT	Utility	
FS	Granted	
LN/CNT	718	
INCL	INCIM: 424/851.000	
INCL	INCIM: 530/350.00; 530/351.000; 514/002.000; 514/008.000; 514/012.000;	
INCL	424/545.000; 424/158.00; 435/240.200	
INCL	424/545.00; 424/545.000; 424/545.000; 435/375.000; 514/002.000; 514/008.000;	
INCL	424/198.10; 424/545.000; 435/375.000; 514/002.000; 514/008.000;	
INCL	514/012.000; 530/350.000; 530/351.000	
IC	[6]	
EXF	424/85.5	
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.	
L8	ANSWER 29 OF 49 USPATFULL	
AN	93:5/4849 USPATFULL	
TI	Lymphokine SAF and method of making	
IN	Dereittas, Blaine C., Villanova, PA, United States	
PA	Abams, J. Todd, Narberth, PA, United States (U.S. corporation)	
PI	The Wistar Institute, Philadelphia, PA, United States	
AI	US 5,225,35	19930706
DT	Utility	
FS	Granted	
LN/CNT	678	
INCL	INCIM: 530/351.000	
INCL	INCIM: 424/085.100	
INCL	INCIM: 530/351.000	
INCL	INCIM: 424/085.100	
IC	[5]	
ICM:	C07K015-00	
ICG:	530/351; 424/85.1	
EXF		
L8	ANSWER 30 OF 49 USPATFULL	
AN	93:22478 USPATFULL	
TI	Temporal gamma-interferon administration for allergies	
IN	Jardieu, Paula M., Belmont, CA, United States	
PA	Gentetech, Inc., South San Francisco, CA, United States (U.S. corporation)	
PI	US 5,186,191	19910323
AI	US 1,931-774429	1991010 (7)
DT	Utility	
FS	Granted	
LN/CNT	432	
INCL	INCIM: 424/085.500	
INCL	INCIM: 424/085.500	
INCL	INCIM: 424/085.500	
IC	[5]	
ICM:	A61K037-66	
EXF		
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.	
L8	ANSWER 31 OF 49 USPATFULL	
AN	92:3/8161 USPATFULL	
TI	Temporal gamma-interferon administration for allergies	
IN	Jardieu, Paula, Belmont, CA, United States	
PA	Gentetech, Inc., South San Francisco, CA, United States (U.S. corporation)	
PI	US 5,112,605	19920512
AI	US 1,989-325406	19890317 (7)
DT	Utility	
FS	Granted	
LN/CNT	440	
INCL	INCIM: 424/085.500	
INCL	INCIM: 424/085.500	
IC	[5]	
ICM:	A61K037-66	
EXF		
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.	

L8 ANSWER 32 OF 49 USPATFULL  
 91-48351 USPATFULL  
 Transient expression system for producing recombinant protein  
 TI  
 IN Gormann, Cornelia M., San Francisco, CA, United States  
 PA Gentech, Inc., South San Francisco, CA, United States (U.S.  
 corporation)  
 PI US 5034939  
 AI 19910618  
 RLI 1987-10171; 1987025 (7)  
 Continuation-in-part of Ser. No. US 1987-71674, filed on 9 Jul 1987, now  
 abandoned which is a continuation-in-part of Ser. No. US 1986-907185,  
 filed on 12 Sep 1986, now abandoned  
 DT Utility  
 FS Granted  
 LN CNT 1597  
 INCL INCLM: 435/065.100  
 INCLS: 435/172.100  
 NCL INCLM: 435/065.100  
 NCLS: 435/461.000; 435/466.000  
 IC [5]  
 ICM: C12N015.67  
 EXF 435/68; 435/172.3; 435/235; 435/320; 435/69.1; 935/32; 935/34; 935/27;  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L8 ANSWER 33 OF 49 USPATFULL  
 90-59326 USPATFULL  
 Methods and compositions for the treatment of lung conditions  
 TI  
 IN Ammann, Arthur J., San Rafael, CA, United States  
 PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
 corporation)  
 PI US 4944941  
 AI 1987-33605  
 DT Utility  
 FS Granted  
 LN CNT 921  
 INCL INCLM: 424/085.500  
 INCLS: 424/085.500  
 NCL NCLM: 424/085.500  
 NCLS: 424/085.100  
 IC [5]  
 ICM: A61K037-61;  
 ICS: A61K037-01;  
 EXP 424/05.1; 422/05.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L8 ANSWER 34 OF 49 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 1997-145063 BIOSIS  
 TI Multiple pathways for lymphotxin (LT) to affect lymph node genesis and  
 lymphocyte organization.  
 AU Renner, P. D.; Krown, J. L.; Hochman, P. S.  
 CS Biogen, Inc., Cambridge, MA USA  
 SO Journal of Allergy and Clinical Immunology, (1997) Vol. 99, No. 1 PART 2,  
 PP. S379.  
 Meeting Info.: Joint Meeting of the American Academy of Allergy, Asthma  
 and Immunology, the American Association of Immunologists and the Clinical  
 Immunology Society San Francisco, California, USA February 21-26, 1997  
 ISSN: 0891-6759.  
 DT Conference; Abstract  
 LA English  
 L8 ANSWER 35 OF 49 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 1996-50577 BIOSIS  
 PREV199799285258  
 TI  
 L8 ANSWER 36 OF 49 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 1996-53142 BIOSIS  
 PREV199699073788  
 TI Normal development of lymph nodes is disrupted by soluble LT  
 beta receptor-fusion protein.  
 AU Renner, P. J.; Browning, J. L.; Hochman, P. S.  
 CS Biogen, Inc., 14 Cambridge Cent., Cambridge, MA 02142 USA  
 SO European Cytokine Network, (1996) Vol. 7, No. 2, pp. 167.  
 Meeting Info.: 6th International Tumor Necrosis Factor Congress Rhodes,  
 Greece May 8-12, 1996  
 ISSN: 1148-5493.  
 DT Conference  
 LA English  
 L8 ANSWER 37 OF 49 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 1993-74379 BIOSIS  
 PREV199395039379  
 TI Insulitis in transgenic mice expressing tumor necrosis factor beta  
 (lymphotoxin) in the pancreas.  
 AU Picarella, Dominic E. (1); Kratz, Alexander; Li, Chang-Ben; Ruddell, Nancy  
 CS (1) Sect. Immunobiol., Yale Univ. Sch. Med., New Haven, Conn. 06510 USA  
 SO Proceedings of the National Academy of Sciences of the United States of  
 America, (1992) Vol. 89, No. 21, pp. 10036-10040.  
 ISSN: 0027-8424.  
 DT Article  
 LA English  
 L8 ANSWER 38 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 97358725 EMBASE  
 DN 1991358725  
 TI Peyer's patch organogenesis - Cytokines rule, ok?  
 AU Mayrhofer, G.  
 CS Prof. G. Mayrhofer, Adelaide/Arthritis Res. Lab. Univ., Hanson Centre for  
 Cancer Research, Inst. of Medical/Veterinary Science, Adelaide, SA,  
 Australia  
 SO Gut, (1997) 41/5 (707-709).  
 Refs: 20  
 ISSN: 0017-5749 CODEN: GUTTAK  
 CY United Kingdom  
 DT Journal; General Review  
 FS 021  
 026 Developmental Biology and Teratology  
 026 Immunology, Serology and Transplantation  
 SL English  
 L8 ANSWER 39 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 97287130 EMBASE  
 DN 1997267130  
 TI Adenovirus-mediated blockade of lymphotoxin-*beta*-  
 inhibits the induction of contact sensitivity in mice.  
 AU Trueb R.M.; Brown G.R.; Dougherty I.; Valdez-Silva M.; Cruz P.D. Jr.

CS P.D. Cruz Jr., Department of Dermatology, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9069, United States.  
pcrus@mednet.swmed.edu  
Experimental Dermatology, (1997) 6/4 (175-180).  
Refs: 13  
ISSN: 0906-6705 CODEN: EXDSEY

CY Denmark; Article  
DT Journal; Article  
FS 013 Dermatology and Venereology  
LA Immunology, Serology and Transplantation  
SL English

L8 ANSWER 40 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
AN 97155057 EMBASE  
TI Human TNF receptor-associated factor 5 (TRAF5): cDNA cloning, expression and assignment of the TRAF5 gene to chromosome 1q32.  
AU Nakano H.; Shindoh M.; Yamada K.; Yoshida M.C.; Saito S.M.; Ware C.F.; Jenkins N.A.; Gilbert D.J.; Yagita H.; Copeland N.G.; Okumura K.  
CS H. Nakano, Department of Immunology, Juntendo Univ. School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113, Japan, hnakano@med.juntendo.ac.jp  
Gencomics, (1997) 42/1 (28-32).  
Refs: 44  
ISSN: 0888-7543 CODEN: GNMCP

CY United States  
DT Journal; Article  
FS 022 Human Geriatrics  
LA English

L8 ANSWER 41 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
AN 97139554 EMBASE  
TI Lymphotxin-alpha-deficient and TNF receptor-1-deficient mice define developmental and functional characteristics of germinal centers.  
AU Matsushita M.; Fu Y.-X.; Molina H.; Chaplin D.D.  
CS D.-D. Chaplin, Center for Immunology, Division of Allergy and Immunology, Washington Univ. School of Medicine, 6600 South Euclid Ave., St. Louis, MO 63110, United States. chaplin@im.wustl.edu  
SO Immunological Reviews, (1997) 156/- (137-144).  
Refs: 40  
ISSN: 0105-2896 CODEN: IMRED2  
CY Denmark; Journal; General Review  
FS 026 Immunology, Serology and Transplantation  
LA 029 Clinical Biochemistry  
SL English

L8 ANSWER 42 OF 49 IMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
AN 97095494 EMBASE  
TI Lymphotxin-beta receptor signaling complex: Role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappa-B.  
AU Vanarsdale T.L.; Vanarsdale S.L.; Force W.R.; Walter B.N.; Mosalos G.; Kieff E.; Reeds J.C.; Ware C.F.  
CS C.F. Ware, Division of Molecular Immunology, La Jolla Allergy/Immunology Inst., 1035 Science Center Drive, San Diego, CA 92121, United States of America, (1997) 94/6 (2460-2465).  
Refs: 62

CY United States; Journal; Article  
FS 029 Clinical Biochemistry  
LA English

L8 ANSWER 43 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
AN 97043104 EMBASE  
TI Human tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NF kappa B activation.  
AU Okumura K.; Inoue J.; Ishida T.; Horie R.; Nagai M.; Ito K.; Yagita H.; T. Watanabe, Dept. of Pathology, Inst. of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108, Japan.  
SO Journal of Biological Chemistry, (1997) 272/4 (2042-2045).  
Refs: 28  
ISSN: 0021-9258 CODEN: JBCHA3

CY United States; Journal; Article  
DT Journal; Clinical Biochemistry  
FS 029 Clinical Biochemistry  
LA English

L8 ANSWER 44 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
AN 97022337 EMBASE  
TI T cell cytokines and disease prevention.  
AU Wood P.R.; Seow H.-F.  
CS H.-F. Seow, CSIRO Division of Animal Health, Private Bag No. 1, Parkville, Vic. 3052, Australia  
SO Veterinary Immunology and Immunopathology, (1996) 54/1-4 (33-44).  
Refs: 86  
ISSN: 0165-2427 CODEN: VIMDSD  
PUI S 0165-2427(96)05711-X  
CY Netherlands; Journal; Conference Article  
DT Conference Article  
FS 026 Immunology, Serology and Transplantation  
LA English  
SL English

L8 ANSWER 45 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
AN 96272529 EMBASE  
TI Adenoviral gene transfer of a lymphotxin-beta inhibitor protein versus gene-targeted lymphotxin-alpha knockout: Effect on delayed-type cutaneous hypersensitivity versus abnormal development of peripheral lymphoid tissues in lymphotxin-alpha-deficient mice.  
AU Trueb R.M.; Cruz P.D.; Dougherty I.; Brown G.; van Huffel C.; Valdez-Silva M.; Beutler B.  
CS Department of Dermatology, University Hospital, Zurich, Switzerland  
SO Dermatology, (1996) 195/2 (14).  
ISSN: 1018-8665 CODEN: DERRAG  
CY Switzerland; Journal; Conference Article  
DT Journal; Conference Article  
FS 013 Dermatology and Venereology  
LA English

L8 ANSWER 46 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
AN 96266842 EMBASE  
DN 1996266842

TI Proinflammatory responses are efficiently induced by homotrimeric but not heterotrimeric lymphotoxin ligands.  
 AU Hochman P.S.; Mijehu G.R.; Mackay F.; Browning J.L.  
 CS Biogen, 14 Cambridge Center, Cambridge, MA 02112, United States  
 SO Journal of Inflammation, (1995) 46/4 (220-234).  
 ISSN: 1078-7852 CODEN: JOINBE  
 CY United States  
 DT Journal; Article;  
 FS 016 Cancer  
 026 Immunology; Serology and Transplantation  
 030 Pharmacology  
 037 Drug Literature Index  
 LA English  
 SL English  
 L8 ANSWER 47 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 9521248 EMBAS:  
 DN 1995218248  
 TI Mechanism of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.  
 AU Warzocha K.; Biunvenu J.; Coiffier B.; Salles G.  
 CS Service d'Hematologie, Centre Hospitalier Lyon-Sud, 69495 Pierre-Benite Cedex, France  
 SO European Cytokine Network, (1995) 6/2 (83-96).  
 ISSN: 1148-5493 CODEN: ECYNET  
 CY France  
 DT Journal; General; Review  
 FS 026 Immunology; Serology and Transplantation  
 029 Clinica; Biochemistry  
 LA English  
 SL English  
 L8 ANSWER 48 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 95006487 EMBAS:  
 DN 1995006487  
 TI Characterization of surface lymphotoxin forms: Use of specific monoclonal antibodies and soluble receptors.  
 AU Browning J.L.; Ilogas I.; Ngan-Ek A.; Bourdon P.R.; Ehrenfeld B.N.; Miatkowski K.; Iaffai M.; Yampaglia A.M.; Lawton P.; Meier W.; Benjamin C.P.; Hession C.  
 CS Department of Cell Biology, Biogen Inc., 14 Cambridge Center, Cambridge, MA 02142, United States  
 SO Journal of Immunology, (1995) 154/1 (33-46).  
 ISSN: 0022-1767 CODEN: JIMMA3  
 CY United States  
 DT Journal; Article  
 FS 026 Immunology; Serology and Transplantation  
 029 Clinical Biochemistry  
 LA English  
 SL English  
 L8 ANSWER 49 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 94102228 EMBASE  
 DN 1994102228  
 TI Tumor necrosis factor alpha (TNF-.alpha.) and TNF-.beta. and their receptors in experimental cutaneous leishmaniasis.  
 AU De Kossodo S.; Grau G.E.; Louis J.A.; Muller I.  
 CS Department of Dermatology, Texas Univ. Southwestern Med. Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9050, United States  
 SO Infection and Immunity, (1994) 62/4 (1414-1420).  
 ISSN: 0019-9567 CODEN: INFIR  
 CY United States  
 DT Journal; Article  
 FS 004 Microbiology

026 Immunology; Serology and Transplantation  
 029 Clinical Biochemistry  
 LA English  
 SL English  
 => d 18 36 all

L8 ANSWER 36 OF 49 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 AN 199635144 BIOSIS  
 DN PREV19659013798  
 TI Normal development of lymph nodes is disrupted by soluble  $\alpha$ - $\beta$  receptor- $\gamma$  fusion protein.  
 AU Renart, P. J.; Browning, J. L.; Hochman, P. S.  
 CS Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142 USA  
 SO European Cytokine Network, (1996) Vol. 7, No. 2, pp. 167.  
 ISSN: 1148-5493.  
 DT Conference  
 LA English  
 CC General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Articles \*0520  
 BC Biochemical Studies - Proteins, Peptides and Amino Acids \*10064  
 Biophysics  
 Membrane Phenomena \*10508  
 Cardiovascular System - Physiology and Biochemistry \*14504  
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System \*15008  
 Endocrine System - General \*17002  
 Developmental Biology - Embryology - General and Descriptive \*25502  
 Developmental Biology - Embryology - Morphogenesis, General \*22502  
 Immunology and Immunohistochemistry - General, Methods \*34502  
 IT Muridae \*83375  
 BC Muridae \*83375  
 TI Major Concepts  
 Blood and Lymphatics (Transport and Circulation); Cardiovascular System (Transport and Circulation); Development; Endocrine System (Chemical Coordination and Coordination and Homeostasis); Immune System (Chemical Coordination and Homeostasis); Membranes (Cell Biology)  
 IT Miscellaneous Descriptors  
 EMBRYONIC CIRCULATION; IMMUNOGLOBULIN G; LYMPHOXIN - $\alpha$ ; MEETING ABSTRACT; MOUSE Yolk SAC; TUMOR NECROSIS FACTOR  
 ORGN Super Taxa  
 Muridae; Rodentia, Mammalia, Vertebrata, Chordata, Animalia  
 ORGN Organism Name  
 Muridae (Muridae)  
 ORGN Organism Superterms  
 animals; chordates; mammals; nonhuman vertebrates; nonhuman mammals; rodents; vertebrates

=> d his

(FILE 'HOME' ENTERED AT 11:53:49 ON 07 AUG 2002)  
 FILE 'MEDLINE, CANCERLIT, CARPIUS, USPATFULL, BIOSIS, CONFSCI, EMBASE'  
 ENTERED AT 11:54:59 ON 07 AUG 2002  
 L1 84 S TNF (A) FUSION?  
 L2 32 S LI AND IMMUNOCLOB?  
 L3 27304 S TUMOR NECROSIS FACTOR OR TNF (A) FUSION?  
 L4 1661 S L3 AND IMMUNOCLOB?  
 L5 1555 S L4 AND LI (A) BETA OR LYMPHOTOXIN (A) BETA  
 L6 392 S L5 AND IMMUNOCLOB?



CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199612  
Entered STN: 19970128  
Last Updated on STN: 19970128  
Entered Medline: 19961230

L13 ANSWER 7 OF 9 MEDLINE  
AN 94316627 MEDLINE  
DN 94316627 Published ID: 7518925  
TI Tumor necrosis factor alpha is an autocrine growth factor for normal human  
B cells.  
AU Bouscoulis V A; Nadler L M; Strominger J L; Goldfield A E  
CS Division of Hematologic Malignancies, Dana-Farber Cancer Institute,  
Boston, MA.  
NC CA47554 (NCI)  
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF  
AMERICA (1994 Jul 19) 91 (15) 7007-11.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journal;  
EM 199408  
ED Entered STN: 19970128  
Last Updated on STN: 19980206  
Entered Medline: 19940822

L13 ANSWER 8 OF 9 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 1996-351442 BIOSIS  
DN PREV199639073798  
TI Normal development of lymph nodes is disrupted by soluble **IL**  
**beta** receptor-**IG** fusion protein.  
AU Bennett, P. J.; Farrowing, J. L.; Hochman, P. S.  
CS Biogen, Inc., 14 Cambridge Cen., Cambridge, MA 02142 USA  
European Cytokine Network, (1996) Vol. 7, No. 2, pp. 167.  
Meeting Info.: 6th International Tumor Necrosis Factor Congress Rhodes,  
Greece May 8-12, 1996  
ISSN 1148-5493.

DR Conference  
LA English

L13 ANSWER 9 OF 9 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 1978112347 BIOSIS  
DN BA65-9347  
TI INHIBITION OF HUMAN LYMPHOCYTE MEDIATED MITOGEN INDUCED CYTO TOXICITY OF  
MURINE L-929 CELL, BY HETEROLOGOUS ANTI HUMAN LYMPHO TOXIN ANTI SERA  
IN-VITRO.  
AU Hisekot, J C; Grainger, G A  
CS DEP. MOL. BIOL. BIOCHEM., UNIV. CALIF. IRVINE, IRVINE, CALIF. 92717, USA.  
SO J IMMUNOL., (1977), 119 (2), 374-380.  
CODEN: JOIMAS. ISSN: 0022-1767.  
FS BA; OLD  
LA English